BeOne Medicines Presents 52.4% Efficacy of Sonrotoclax at ASH Meeting
Written by Emily J. Thompson, Senior Investment Analyst
Source: Businesswire
Updated: 1 hour ago0mins
- Clinical Data Highlight: At the American Society of Hematology Annual Meeting, BeOne Medicines showcased sonrotoclax's 52.4% overall response rate (ORR) in relapsed/refractory (R/R) mantle cell lymphoma, indicating its potential as a monotherapy and possibly the first BCL2 inhibitor approved in the U.S.
- Rapid Response Advantage: Sonrotoclax demonstrated a median time to response of 1.9 months, with an ORR of 76% in treatment-naive chronic lymphocytic leukemia (CLL) patients, highlighting its significant potential to improve patient outcomes rapidly.
- Good Tolerability: The monotherapy with sonrotoclax was generally well tolerated, with manageable adverse events such as neutropenia occurring in 19.1% of patients, establishing a solid foundation for its future clinical applications.
- FDA Priority Review: The drug is currently under Priority Review by the U.S. FDA, and if approved, it will provide a new treatment option for R/R MCL patients, addressing the urgent market demand for new therapies.
06160.HK
$0.0000%Past 6 months
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
No Data
Powered By
Intellectia
Analyst Views on 06160
Wall Street analysts forecast 06160 stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for 06160 is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
0 Analyst Rating
0 Buy
0 Hold
0 Sell
Current: 200.400
Low
Averages
High
Current: 200.400
Low
Averages
High
CCBI
CCBI
upgrade
$230 -> $234
2025-11-10
Reason
CCBI
CCBI
Price Target
$230 -> $234
2025-11-10
upgrade
Reason
The analyst rating for BEONE MEDICINES is "Outperform" based on several key factors highlighted in the article. The company turned around from a significant loss in the previous quarter to a net profit that exceeded market expectations, reporting a profit of $125 million in 3Q25 compared to the consensus estimate of $80 million. Additionally, total product revenue for the quarter increased by 40% year-over-year, aligning with the broker's forecasts. CCBI also raised its target price for the stock, reflecting a positive outlook based on a sum-of-the-parts valuation method and discounted cash flow analysis, which suggests that the stock is undervalued compared to its peers in the biotech sector.
See All Ratings
About the author
Preview
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Sigh Up to Get Intellectia Insights
How did the company's recent strategic decisions impact its latest financial performance?
Can you explain the factors behind the recent changes in the company's stock price?
What are the expected impacts of current market trends on the company's future growth?
Based on the latest earnings report, what are the company's forecasted revenues for the next quarter?